Pre-treatment bicarbonate levels and decongestion by acetazolamide: the ADVOR trial

Author:

Martens Pieter12ORCID,Verbrugge Frederik H34,Dauw Jeroen25,Nijst Petra2ORCID,Meekers Evelyne23,Augusto Silvio Nunes6,Ter Maaten Jozine M7,Heylen Line8ORCID,Damman Kevin7ORCID,Mebazaa Alexandre9,Filippatos Gerasimos10ORCID,Ruschitzka Frank11,Tang Wai Hong Wilson1,Dupont Matthias2ORCID,Mullens Wilfried25ORCID

Affiliation:

1. Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic , Cleveland, OH , USA

2. Department of Cardiology, Ziekenhuis Oost-Limburg A.V. , Schiepse bos 6, 3600 Genk , Belgium

3. Centre for Cardiovascular Diseases, University Hospital Brussels , Jette , Belgium

4. Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel , Jette , Belgium

5. Faculty of Medicine and Life Science, Hasselt University , Martelarenlaan 42, 3500 Hasselt , Belgium

6. Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic , Cleveland, OH , USA

7. Department of Cardiology, University Medical Center Groningen, University of Groningen , Groningen , The Netherlands

8. Department of Nefrology, Ziekenhuis Oost-Limburg A.V. , Genk , Belgium

9. Department of Medicine, Université Paris Cité, Inserm MASCOT, APHP , Paris , France

10. Department of Cardiology, National and Kapodistrian University of Athens, Athens University Hospital Attikon , Athens , Greece

11. Department of Cardiology, University Heart Center, University Hospital Zurich and University of Zurich , Zurich , Switzerland

Abstract

Abstract Aims Acetazolamide inhibits proximal tubular sodium and bicarbonate re-absorption and improved decongestive response in acute heart failure in the ADVOR trial. It is unknown whether bicarbonate levels alter the decongestive response to acetazolamide. Methods and results This is a sub-analysis of the randomized, double-blind, placebo-controlled ADVOR trial that randomized 519 patients with acute heart failure and volume overload in a 1:1 ratio to intravenous acetazolamide (500 mg/day) or matching placebo on top of standardized intravenous loop diuretics (dose equivalent of twice oral maintenance dose). The primary endpoint was complete decongestion after 3 days of treatment (morning of day 4). Impact of baseline HCO3 levels on the treatment effect of acetazolamide was assessed. : Of the 519 enrolled patients, 516 (99.4%) had a baseline HCO3 measurement. Continuous HCO3 modelling illustrated a higher proportional treatment effect for acetazolamide if baseline HCO3 ≥ 27 mmol/l. A total of 234 (45%) had a baseline HCO3 ≥ 27 mmol/l. Randomization towards acetazolamide improved decongestive response over the entire range of baseline HCO3− levels (P = 0.004); however, patients with elevated baseline HCO3 exhibited a significant higher response to acetazolamide [primary endpoint: no vs. elevated HCO3; OR 1.37 (0.79–2.37) vs. OR 2.39 (1.35–4.22), P-interaction = 0.065), with higher proportional diuretic and natriuretic response (both P-interaction < 0.001), greater reduction in congestion score on consecutive days (treatment × time by HCO3-interaction <0.001) and length of stay (P-interaction = 0.019). The larger proportional treatment effect was mainly explained by the development of diminished decongestive response in the placebo arm (loop diuretics only), both with regard to reaching the primary endpoint of decongestion as well as reduction in congestion score. Development of elevated HCO3 further worsened decongestive response in the placebo arm (P-interaction = 0.041). A loop diuretic only strategy was associated with an increase in the HCO3 during the treatment phase which was prevented by acetazolamide (day 3: placebo 74.8% vs. acetazolamide 41.3%, P < 0.001). Conclusion Acetazolamide improves decongestive response over the entire range of HCO3− levels; however, the treatment response is magnified in patients with baseline or loop diuretic-induced elevated HCO3 (marker of proximal nephron NaHCO3 retention) by specifically counteracting this component of diuretic resistance.

Funder

Belgian Health Care Knowledge Centre

Belgian American Educational Foundation

Frans Van de Werf Fund

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3